Ami Organics gets 79 percent of the revenue comes from pharma space wherein it manufactures intermediates for APIs and NCE (New Chemical Entities). Rest of the revenue comes from chemicals segment. While company’s foray into the lithium-ion batteries and the semiconductor industry value chain is a key watch, ramp-up in CDMO (Contract Development and Manufacturing Organization) contracts is expected to be the key earnings catalyst.
first published: Jan 8, 2025 08:00 am
A collection of the most-viewed Moneycontrol videos.
Live: Nifty holds above 25,900 but off nearly 100 pts from day's high | Closing Bell
Live: Will Nifty reclaim 26,000-mark amid record low inflation in Oct? | Opening Bell
Live: Nifty extends gain to third day, above 25,850 amid broad-based buying | Closing Bell
Live: Can Nifty approach 25,800-mark and extend gains to third day? | Opening Bell
